Nektar Therapeutics News (NASDAQ:NKTR)
| Latest Nektar Therapeutics News Headlines | | Date | Time | Source | | | 06/02/2008 | 8:31AM | PRNUS | Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
Phase 2 Study for NKTR-102 Will Target Newly-Identified K-Ras Mutated Oncogene Population in Patients with Advanced Colorectal Cancer
SAN CARLOS, Calif., June 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company... More...>> |
| 06/02/2008 | 8:30AM | PRNUS | New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar's Innovative Small Molecule PEG-Oncolyti
SAN CARLOS, Calif., June 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced new positive data today from a Phase 1 clinical study for NKTR-102 (PEG-irinotecan) in advanced cancer patients whose tumors had progressed on other therapies. Significant anti-tumor activity was observed in all dose schedules... More...>> |
| 05/30/2008 | 8:30AM | PRNUS | Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotec
SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featured speaker Dr. Daniel D... More...>> |
| 05/22/2008 | 8:00AM | PRNUS | Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
SAN CARLOS, Calif., May 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that Bharatt Chowrira, Ph.D., J.D. has joined the Company as Chief Operating Officer and Head of the PEGylation Business Unit. His responsibilities include overseeing and managing all aspects of the PEGylation Business... More...>> |
| 05/19/2008 | 1:30PM | PRNUS | Amikacin Inhale Shows Promising Results in Phase II Study
- Bayer together with Nektar Therapeutics present preliminary Phase II data for the adjunctive treatment of pneumonia in intubated and mechanically-ventilated patients
TORONTO and BERLIN, May 19 /PRNewswire-FirstCall/ -- Bayer HealthCare together with Nektar Therapeutics (NASDAQ:NKTR), today presented positive preliminary... More...>> |
| 05/16/2008 | 8:30AM | PRNUS | Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Procee
Nektar's Technology Enables First-Ever PEGylation of a Small Molecule with Demonstrated Therapeutic Activity
SAN CARLOS, Calif., May 16 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor... More...>> |
| 05/12/2008 | 9:00AM | PRNUS | Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) highlighted today that its proprietary PEGylation technology is used in the novel therapeutic, Hematide(TM), a synthetic, peptide-based erythropoiesis-stimulating agent that is under development by Takeda Global Research & Development... More...>> |
| 05/07/2008 | 4:25PM | PRNUS | Nektar Therapeutics Announces First Quarter 2008 Results
SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today the company's financial results for the first quarter ended March 31, 2008.
Cash, cash equivalents, and short-term investments were $412.6 million at March 31, 2008 compared to $482.4 million at December 31, 2007.
Nektar... More...>> |
| 05/07/2008 | 4:10PM | PRNUS | Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
U.S. Patent Encompassing Tobramycin Inhalation Powder and Other Aminoglycoside Antibiotics Issued to Nektar
SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the U.S. Patent and Trademark Office has issued Patent No. 7,368,102, which covers compositions and methods... More...>> |
| 05/07/2008 | 9:00AM | PRNUS | NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Socie
SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics (NASDAQ:NKTR) this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida. In this multiple-dose Phase 1 study, oral NKTR-118 was shown... More...>> |
| 04/30/2008 | 4:30PM | PRNUS | Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
SAN CARLOS, Calif., April 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the first quarter ended March 31, 2008 on Wednesday, May 7, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference... More...>> |
| 04/23/2008 | 8:00AM | PRNUS | FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Cimzia(R) marks the first FDA approval of a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody
SAN FRANCISCO, April 23 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia(R) (certolizumab pegol) for reducing the signs and symptoms of Crohn's disease and maintaining... More...>> |
| 04/14/2008 | 8:00AM | PRNUS | Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at A
SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (NASDAQ:NKTR) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal cancer when co-administered with... More...>> |
| 04/10/2008 | 8:30AM | PRNUS | Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetings over the coming months. These presentations will highlight Nektar's novel therapeutic... More...>> |
| 04/09/2008 | 8:30AM | PRNUS | Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed i
SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from ongoing clinical trials conducted by Pfizer Inc. An increase in the number... More...>> |
| 02/27/2008 | 4:25PM | PRNUS | Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
SAN CARLOS, Calif., Feb. 27, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today the company's financial results for the fourth quarter and year ended December 31, 2007.
Revenue totaled $65.8 million in the fourth quarter of 2007 compared to $69.9 million in the fourth quarter of 2006... More...>> |
| 02/21/2008 | 5:10PM | PRNUS | Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
SAN CARLOS, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year ended December 31, 2007 on Wednesday, February 27, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will... More...>> |
| 02/12/2008 | 7:01AM | PRNUS | Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
SAN CARLOS, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced a restructuring today designed to complete its transition from a drug delivery service provider to a therapeutics drug development organization. The restructuring will streamline the company, consolidate corporate functions... More...>> |
| 02/12/2008 | 6:55AM | PRNUS | Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Company's Board of Directors
Huh To Step Down as COO and Head of PEGylation Business Unit
SAN CARLOS, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that Hoyoung Huh, M.D., Ph.D, is newly appointed to serve on the Board of Directors of the company. Dr. Huh will step down as Nektar's Chief Operating... More...>> |
| 01/29/2008 | 4:30PM | PRNUS | Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology &
SAN CARLOS, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (NASDAQ:NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference in New York at the Grand Hyatt New York Hotel on Tuesday, February... More...>> |
|
|
|